Aspirin use is associated with an improved long-term survival in an unselected population presenting with unstable angina.

Abstract

BACKGROUND:

Few published data are available on the benefits of aspirin use in patients with unstable angina (UA).

HYPOTHESIS:

Aspirin use carries a mortality benefit in a population-based cohort of patients presenting with UA.

METHODS:

All residents of Olmsted County, Minnesota presenting to local emergency departments with acute chest pain from January 1985 through December 1992 having symptoms consistent with UA were identified through medical records. A total of 1628 patients were identified with UA and were stratified by aspirin use in-hospital and at discharge. Cardiovascular mortality and nonfatal myocardial infarction and stroke were assessed over a median of 7.5 years follow-up and all-cause mortality data over a median of 16.7 years. The mean age of patients with UA was 65 years, and 60% were men.

RESULTS:

After a median of 7.5 years follow-up, all-cause and cardiovascular-mortality rates were lower among patients prescribed versus not prescribed aspirin on discharge. There were 949 postdischarge deaths over the median follow-up of 16.7 years. After multivariable adjustment, aspirin use at discharge was associated with a lower long-term mortality (hazard ratio 0.78; 95% confidence interval, 0.65-0.93).

CONCLUSIONS:

Aspirin use at hospital discharge following UA is associated with a reduction in long-term mortality. This long-term study extends prior trial results from select populations to a population-based cohort.

• Authors: Louai Razzouk, Verghese Mathew, Ryan J Lennon, Ashish Aneja, Joshua I Mozes, Heather J Wiste, Paul Muntner, James H Chesebro, Michael E Farkouh
• Journal: Clinical cardiology (Clin Cardiol) Vol. 33 Issue 9 Pg. 553-8 (Sep 2010) ISSN: 1932-8737 [Electronic] United States
• PMID: 20842739 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
• Copyright: Copyright © 2010 Wiley Periodicals, Inc.

Chemical References

• Fibrinolytic Agents
• Platelet Aggregation Inhibitors
• Aspirin

Topics

• Acute Disease
• Aged
• Aspirin (therapeutic use)
• Confidence Intervals
• Female
• Fibrinolytic Agents (therapeutic use)
• Humans
• Kaplan-Meier Estimate
• Male
• Middle Aged
• Minnesota
• Multivariate Analysis
• Patient Discharge
• Platelet Aggregation Inhibitors (therapeutic use)
• Proportional Hazards Models
• Retrospective Studies
• Time Factors